About Covalab
Covalab is a company based in Villeurbanne (France) founded in 1995. Covalab operates in a competitive market with competitors including Abcam, Stem Cell Technologies, OriGene, Sangon Biotech and Meridian Bioscience, among others.
- Headquarter Villeurbanne, France
- SectorsHealthcare
- Phone•••• ••••
- Website covalab.com
- Social LinkedIn
- Legal Name Coval
- Latest Funding Round$185.05K (USD), Grant
Oct 2023
- Investors
Funding Insights of Covalab
- Total Rounds 1
- Last Round Grant — $185,052
- First Round $185,052
(Oct 2023)
- Investors Count 1
All 1 funding rounds of Covalab with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2023 | $185,052 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in Covalab
Covalab has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Covalab
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Covalab
2 dated milestones of Covalab across 28 years, from founding to its latest funding, stage changes and deals.
- Founded Covalab is founded.
- Funding First funding round of $185K.
Competitors of Covalab
Covalab operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Abcam, Stem Cell Technologies, OriGene, Sangon Biotech and Meridian Bioscience, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| abcam.com | 1998 | Cambridge, United Kingdom | $78.8M | 405 | Biological reagents and antibodies are developed for life science research. | |
| stemcell.com | 1993 | Vancouver, Canada | $11.92M | 129 | Developer of cell culture media and ancillary reagents for life science research | |
| origene.com | 1996 | Rockville, United States | $69.55M | 141 | Proteins, antibodies, and molecular tools are manufactured for research applications. | |
| sangon.com | 2003 | Shanghai, China | $300M | – | Research services, reagents, and kits for biotech applications are provided. | |
| meridianbioscience.com | 1976 | Ohio, United States | – | – | Molecular diagnostic device and kits | |
| teknova.com | 1996 | Hollister, United States | – | 290 | Molecular biology reagents and kits are supplied for research applications. | |
| caymanchem.com | 1980 | Ann Arbor, United States | – | 309 | Bioreagents and assay kits are developed, with preclinical services provided. | |
| abclonal.com | 2006 | Woburn, United States | $281.25M | – | Developer of protein and peptide reagents and kits for cell and molecular biology research | |
| seracare.com | 1984 | Milford, United States | – | – | Provider of biological materials/products that help optimize diagnostic performance, reliability and repeatability |
Detailed competitors of Covalab
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Covalab
The website of Covalab (covalab.com) receives about 5.3K visits a month.
- Monthly visits5.3K
▼ 14.7% vs previous month
Websites whose visitors overlap most with Covalab. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
origene.com.cn | origene.com.cn | 100% | – | – | – |
| biorbyt.com | 92% | 25.2K | #1,234,075 | View details | |
| mybiosource.com | 91% | – | #238,129 | View details | |
| phoenixpeptide.com | 89% | 102.4K | #300,152 | View details | |
| abcam.com | 88% | 602.8K | #91,958 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 26 similar websites and full traffic analytics for Covalab
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Similar companies to Covalab
10 companies that operate in the same segment as Covalab (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Covalab
Covalab was founded in 1995 and raised its 1st funding round 28 years after it was founded.
Covalab is headquartered in Villeurbanne, France. It is registered at Villeurbanne, Auvergne-rhone-alpes, France.
Covalab was established in 1995 in Villeurbanne, France, within the biotechnology sector. Focus is placed on chemical modifications of antigens and antibodies. A portfolio of products is maintained, encompassing primary and secondary antibodies, peptides, proteins, reagents, and kits. Custom services are extended, including polyclonal and monoclonal antibody development, immunization, purification methods, fragmentation, and labeling. Operations support research applications across immunology and related fields.
Covalab's top competitors include Abcam, Meridian Bioscience and Stem Cell Technologies.
Covalab has 1 investor. Key investors include European Union.
Covalab operates through Coval.